SCHEDULE 13D/A: Akari Therapeutics' Major Shareholder Dr. Ray Prudo Boosts Stake to 9.3% Following Private Placement

Dr. Ray Prudo, a key reporting person, has increased his beneficial ownership in Akari Therapeutics, Plc to 9.3% of outstanding Ordinary Shares following participation in a December 2024 private placement.

Summary

• This Amendment No. 9 to Schedule 13D updates the beneficial ownership of Akari Therapeutics, Plc (AKTX) Ordinary Shares by Ray Prudo, M.D., RPC Pharma Limited, and Praxis Trustees Limited.
• As of February 14, 2025, Dr. Ray Prudo, individually and through entities he controls (RPC Pharma Limited and Praxis Trustees Limited), beneficially owns an aggregate of 4,926,600,800 Ordinary Shares, representing approximately 9.3% of the Issuer's outstanding Ordinary Shares.
• This aggregate includes 4,077,124,600 Ordinary Shares directly held by Dr. Prudo, options to purchase 10,000,000 Ordinary Shares exercisable within 60 days, 38,709,600 Ordinary Shares held by Praxis, and 800,766,600 Ordinary Shares held by RPC.
• On December 2, 2024, Dr. Prudo participated in a private placement (November 2024 PIPE), purchasing 209,643 American Depositary Shares (ADSs), representing 419,286,000 Ordinary Shares, and Series D Warrants to purchase an additional 419,286,000 Ordinary Shares.
• The combined unit price for the ADSs and Series D Warrants in the private placement was $2.385 per ADS, funded by Dr. Prudo's personal funds.
• The percentage of beneficial ownership is based on 53,186,919,523 Ordinary Shares issued and outstanding as of February 14, 2025.
• Dr. Prudo also holds warrants to purchase 1,932,587,500 Ordinary Shares, but disclaims beneficial ownership of these warrants and their underlying securities to the extent that exercise would exceed a 9.99% beneficial ownership limitation.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. The increase in beneficial ownership by a key insider through a private placement suggests continued confidence and investment in the company, which is generally viewed favorably. However, the document is purely a disclosure of ownership and does not contain operational or financial performance updates.

Positives

• A significant insider, Dr. Ray Prudo, has increased his beneficial ownership in Akari Therapeutics, indicating continued confidence in the company's prospects.
• The participation of a major shareholder in the private placement demonstrates a commitment to the company's financing efforts.

Risks

• Dr. Prudo's warrants to purchase 1,932,587,500 Ordinary Shares are subject to a 9.99% beneficial ownership limitation, meaning he disclaims beneficial ownership beyond this threshold, which could limit his ability to fully exercise these warrants if it pushes his ownership above the cap.

Future Outlook

The document does not provide explicit forward-looking statements or guidance regarding the company's future operations or financial performance, focusing solely on beneficial ownership changes.

Industry Context

This filing is a standard disclosure of a significant shareholder's ownership stake and participation in a private placement, common in the biotechnology or pharmaceutical industry for companies seeking capital. It reflects an individual investor's strategic positioning within the company rather than broader industry trends.

Related Party Transactions

• Dr. Ray Prudo, a reporting person and significant beneficial owner, participated in the November 2024 private placement, purchasing securities from the Issuer. This constitutes a transaction between a related party (Dr. Prudo) and the Issuer.

Stakeholder Impact

• Shareholders may view the increased stake by a significant insider, Dr. Ray Prudo, as a positive signal of confidence in the company's future.
• The private placement provides capital to the company, which could support its operations and strategic initiatives.

Key Dates

Keywords

Akari Therapeutics, Schedule 13D, beneficial ownership, private placement, PIPE, Ray Prudo, ordinary shares, ADSs, warrants, shareholder stake, corporate finance